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The intracellular signalling molecule cGMP is involved in
a variety of physiological processes such as smooth mus-
cle relaxation and inhibition of platelet aggregation. The
combination of different cGMP-generating and cGMP-
degrading enzymes, guanylyl cyclases and phosphodieste-
rases, respectively, determines amplitude and shape of
cGMP signals in a given tissue. Fast and transient cGMP
signals that reach up to hundredfold elevated peak con-
centrations within seconds and rapidly return to almost
baseline levels have been observed in neuroblastoma
cells, platelets and smooth muscle cells. Thus, indicators
allowing continuous measurement of cGMP signals in liv-
ing cells are clearly demanded.
Here, we report on an approach to create FRET-based
cGMP indicators using the two known types of cGMP-
binding domains, cNMP-BD and GAF, occurring in the
cGMP-dependent protein kinases and phosphodiesterase
5, respectively. More than 50 constructs containing differ-
ent regions of either isolated or tandem cGMP-binding
domains were created and tested in vitro. Interestingly,
only tandem cGMP-binding domains arranged as in the
cGMP effector proteins were cGMP-responsive. The GAF-
derived indicators showed extremely slow FRET changes
upon cGMP binding and dissociation making them
unsuitable for monitoring fast intracellular cGMP signals.
From the tandem cNMP-BDs of cGMP-dependent protein
kinase a range of functional constructs was obtained.
Three of these indicators with affinities between 500 nM
and 6 μM were chosen to cover a range of intracellular
cGMP concentrations. These indicators feature twice the
dynamic range of existing cGMP sensors, exhibit fast
kinetics, and a high selectivity for cGMP. The in vivo per-
formance is demonstrated in a HEK293 line stably
expressing NO-sensitive guanylyl cyclase and phosphodi-
esterase 5 which displays cGMP signals comparable to the
ones of smooth muscle cells. The signals obtained with
the three cGMP indicators are validated by comparison
with cGMP dynamics measured by radioimmunoassays.
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